Cadrenal Sets Sept. 24 Annual Meeting, Seeks Director Election, Auditor Ratification
Ticker: CVKD · Form: DEF 14A · Filed: Jul 31, 2025 · CIK: 1937993
Sentiment: neutral
Topics: Proxy Statement, Corporate Governance, Annual Meeting, Director Election, Auditor Ratification, Pharmaceuticals, SEC Filing
Related Tickers: CVKD
TL;DR
**CVKD's annual meeting is a routine governance check, but keep an eye on the director election for any strategic shifts.**
AI Summary
Cadrenal Therapeutics, Inc. (CVKD) filed a Definitive Proxy Statement (DEF 14A) on July 31, 2025, for its Annual Meeting of Stockholders scheduled for September 24, 2025, at 10:00 a.m. Eastern Time. The company, a pharmaceutical preparations firm, is headquartered at 822 A1A North, Suite 306, Ponte Vedra, Florida. Key proposals for the meeting include the election of one Class III director to serve a three-year term expiring at the 2028 Annual Meeting and the ratification of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The filing does not disclose specific revenue or net income figures, nor does it detail key business changes or strategic outlook beyond these governance matters. Risks are implicitly tied to standard corporate governance and auditor oversight, with no explicit financial risks detailed in this specific DEF 14A. The company's fiscal year ends on December 31.
Why It Matters
This DEF 14A filing outlines Cadrenal Therapeutics' upcoming annual meeting, a crucial event for corporate governance and investor oversight. The election of a Class III director impacts the company's long-term strategic direction and board composition, directly affecting investor confidence and potential future performance. Ratifying WithumSmith+Brown, PC as the auditor ensures continued financial transparency and regulatory compliance, which is vital for maintaining trust with shareholders and the broader market. In the competitive pharmaceutical sector, strong governance and reliable financial reporting are paramount for attracting and retaining investment, distinguishing Cadrenal from peers.
Risk Assessment
Risk Level: low — The risk level is low as this DEF 14A primarily addresses routine corporate governance matters: the election of one Class III director and the ratification of an independent auditor, WithumSmith+Brown, PC, for the fiscal year ending December 31, 2025. There are no indications of extraordinary proposals, contentious board battles, or significant financial risks detailed within this specific filing.
Analyst Insight
Investors should review the proxy statement for details on the Class III director nominee's qualifications and any potential implications for Cadrenal's strategic direction. Voting on the auditor ratification is standard, but understanding the auditor's history with the company can provide additional context.
Key Numbers
- 1 — Number of Class III directors to be elected (To serve a three-year term expiring at the 2028 Annual Meeting)
- 2025 — Year of Annual Meeting of Stockholders (Meeting to be held on September 24, 2025)
- 2028 — Year of expiration for elected director's term (Three-year term for Class III director)
Key Players & Entities
- Cadrenal Therapeutics, Inc. (company) — Registrant for DEF 14A filing
- WithumSmith+Brown, PC (company) — Independent registered public accounting firm for fiscal year ending December 31, 2025
- SEC (regulator) — United States Securities and Exchange Commission
- September 24, 2025 (date) — Date of the 2025 Annual Meeting of Stockholders
- December 31, 2025 (date) — End of fiscal year for auditor ratification
- 822 A1A North, Suite 306, Ponte Vedra, Florida 32082 (location) — Business address of Cadrenal Therapeutics, Inc.
- Class III director (person) — Nominee for a three-year term on the Board of Directors
FAQ
What is the purpose of Cadrenal Therapeutics' 2025 Annual Meeting?
The 2025 Annual Meeting of Cadrenal Therapeutics, Inc. is being held to elect one Class III director to a three-year term expiring at the 2028 Annual Meeting and to ratify the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
When and where will Cadrenal Therapeutics' 2025 Annual Meeting be held?
The 2025 Annual Meeting of Cadrenal Therapeutics, Inc. will be held virtually on Wednesday, September 24, 2025, at 10:00 a.m. Eastern Time. Stockholders can access the live webcast by visiting www.virtualshareholdermeeting.com/CVKD2025.
Who is Cadrenal Therapeutics' independent registered public accounting firm for 2025?
Cadrenal Therapeutics, Inc. proposes to ratify the appointment of WithumSmith+Brown, PC as its independent registered public accounting firm for the fiscal year ending on December 31, 2025.
What is the term length for the director being elected at Cadrenal Therapeutics' 2025 Annual Meeting?
The one nominee for Class III director named in the accompanying proxy statement will serve a three-year term, expiring at the 2028 Annual Meeting of Stockholders.
What is Cadrenal Therapeutics' business address?
Cadrenal Therapeutics, Inc.'s business address is 822 A1A North, Suite 306, Ponte Vedra, Florida 32082.
What is the fiscal year end for Cadrenal Therapeutics, Inc.?
Cadrenal Therapeutics, Inc.'s fiscal year ends on December 31, as indicated by the auditor ratification for the fiscal year ending December 31, 2025.
Is there a fee required for this Cadrenal Therapeutics DEF 14A filing?
No fee was required for this Definitive Proxy Statement (DEF 14A) filing by Cadrenal Therapeutics, Inc., as indicated by the 'No fee required' checkbox being marked.
What type of company is Cadrenal Therapeutics, Inc.?
Cadrenal Therapeutics, Inc. is classified under Standard Industrial Classification 2834, which corresponds to Pharmaceutical Preparations.
How can Cadrenal Therapeutics stockholders submit questions for the annual meeting?
Additional information regarding submitting questions in advance of the annual meeting can be found in the proxy statement, and the meeting will be held virtually at www.virtualshareholdermeeting.com/CVKD2025.
What are the main proposals for Cadrenal Therapeutics' stockholders to vote on?
Stockholders will vote on two main proposals: the election of one Class III director for a three-year term and the ratification of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Industry Context
Cadrenal Therapeutics operates within the pharmaceutical preparations industry. This sector is characterized by significant research and development investment, stringent regulatory oversight from bodies like the FDA, and a competitive landscape driven by innovation and patent protection. Companies in this space often focus on developing novel therapies for specific medical conditions.
Regulatory Implications
As a pharmaceutical company, Cadrenal Therapeutics is subject to extensive regulatory scrutiny, particularly concerning drug development, clinical trials, and marketing. The ratification of the independent auditor is a standard governance requirement that ensures financial reporting integrity, which is crucial for maintaining investor confidence and regulatory compliance.
What Investors Should Do
- Review the proxy statement details regarding the nominee for Class III director.
- Vote on the ratification of WithumSmith+Brown, PC as the independent registered public accounting firm.
- Attend the virtual 2025 Annual Meeting of Stockholders or vote by proxy.
Key Dates
- 2025-07-31: Filing of Definitive Proxy Statement (DEF 14A) — Provides shareholders with information regarding the upcoming annual meeting and matters to be voted upon, including director elections and auditor ratification.
- 2025-09-24: 2025 Annual Meeting of Stockholders — Key date for shareholders to vote on director nominations and ratification of the independent auditor, influencing corporate governance.
- 2025-12-31: Fiscal Year End — Marks the end of the company's financial reporting period for which the auditor ratification is sought.
- 2028-09-24: Expiration of Elected Director's Term — Indicates the end of the three-year term for the Class III director to be elected at the 2025 Annual Meeting.
Glossary
- DEF 14A
- A Definitive Proxy Statement filed with the SEC by public companies to solicit shareholder votes for an upcoming meeting. (This document outlines the agenda for Cadrenal Therapeutics' annual meeting, including director elections and auditor ratification.)
- Class III director
- A category of directors on a company's board, typically serving staggered three-year terms. (One Class III director is up for election at the 2025 Annual Meeting, with a term expiring in 2028.)
- Independent registered public accounting firm
- An external audit firm that is independent of the company and registered with the PCAOB to perform audits of public companies. (The ratification of WithumSmith+Brown, PC as the auditor for fiscal year 2025 is a key proposal for shareholders.)
- Fiscal Year End
- The last day of a company's accounting period, which is December 31 for Cadrenal Therapeutics. (This date is relevant for the auditor ratification proposal, specifying the period for which the auditor's services are being approved.)
Year-Over-Year Comparison
This filing is a Definitive Proxy Statement (DEF 14A) for the 2025 Annual Meeting. As it focuses on governance matters such as director elections and auditor ratification, it does not contain comparative financial data like revenue or net income from a previous year's filing. Therefore, a direct comparison of key financial metrics or business changes is not possible based solely on this document.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on July 31, 2025 by Class III director regarding Cadrenal Therapeutics, Inc. (CVKD).